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Abstract
Fortunately, with advances in screening and management, the prognosis of breast 
cancer has substantially improved. However, as patients with breast cancer are living 
much longer, consequences of management are becoming increasingly apparent, 
particularly persistent pain after breast cancer surgery. This pain disorder, referred to 
as Post-Mastectomy Pain Syndrome (PMPS) is common and typically presents as pain 
with neuropathic features around the surgical incision. This pain disorder is associated 
with negative effects on the patient’s social and psychological well-being as well as 
increased healthcare expenditures. Despite the common occurrence of this disorder, 
it is vastly under-recognized with a lack of preventative and treatment options. This 
chapter aims to outline the management of persistent breast surgery pain. The patho-
physiology and etiology will be reviewed, followed by tools that clinicians can imple-
ment in order to appropriately diagnose neuropathic pain. Pertinent risk factors that 
are commonly seen in practice will be outlined, followed by non-pharmacological, 
pharmacological, and interventional therapeutic options that can be offered.
Keywords: persistent pain, chronic pain, neuropathy, post-mastectomy pain 
syndrome, intercostobrachial neuralgia, intercostal neuralgia, psychological 
factors, axillary lymph node dissection, postoperative pain, pharmacological therapy, 
interventional therapy, nerve blocks, neuromodulation
1. Introduction
Breast cancer continues to be the most frequently diagnosed cancer in women 
worldwide [1] and cases in the United States are expected to rise by 64% between 
2011 and 2030 [2]. Nonetheless, with significant progress in prevention and treat-
ment over the past 30 years, survivorship has substantially increased [3], most 
notably in women ages 20–39 years [4]. The 5-year relative survival rate for breast 
cancer now approaches 90% [5] and while mortality rates have declined, it presents 
a unique challenge, as long-term complications of breast cancer management are 
becoming increasingly apparent, particularly persistent post-surgical pain.
Persistent pain has become a significant area of concern as it appears to afflict 
up to 50% of women after breast cancer surgery [6]. This pain disorder is typi-
cally neuropathic in nature and described as burning, spontaneous, electrical, 
numbness, tingling, and pinprick pain affecting the area of surgery in the chest, 
shoulder, axilla, and medial arm [7]. While the literature commonly refers to this 
presentation as post-mastectomy pain syndrome (PMPS), it is important to note 
that damage of nerves can occur after all types of breast cancer surgeries, including 
unilateral or bilateral surgeries, radical mastectomies, lumpectomies, and from 
axillary lymph node dissection. Thus, in 2016 Waltho et al. proposed the term 
post-breast surgery pain syndrome (PBSPS) which is not only a more inclusive 
term but may also help to decrease the wide variation in overall prevalence [8]. 
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The International Association for Study of Pain (IASP) also recently updated their 
definition to include all types of breast surgeries in the classification. Thus, the term 
“persistent pain after breast surgery” was chosen, and it is pain which persists for 
more than 3 months after a surgical incision to the anterolateral chest wall and in 
some cases in the ipsilateral axillary region [9].
Management of persistent pain after breast cancer surgery can be a challeng-
ing task with the lack of effective treatment options [10]. Furthermore, this pain 
disorder places a financial burden on both patients and the healthcare system with 
studies showing an estimated cost of approximately $1 billion USD annually to the 
US healthcare system [11]. Identifying perioperative risk factors associated with 
the development of persistent pain can help decrease the incidence and the need for 
ongoing healthcare services.
In this chapter we will provide an outline of the pathophysiology of persistent 
pain after breast cancer surgery, including a review of pertinent risk factors, clinical 
features, and various treatment options.
2. Pathophysiology
Pain can originate from a multitude of sources, such as from injury to the 
overlying skin, tissue, or nerves during surgical intervention, or from the effects of 
radiation and chemotherapy. Additionally, the origin is frequently multifactorial, 
with psychosocial factors also playing a role.
2.1 Nerve injury
Surgical factors can cause nerve injuries that contribute to persistent pain after 
breast cancer surgery. Direct nerve injury, for instance from skin incisions, surgi-
cal retractors, or extensive axillary lymph node dissection, can lead to direct nerve 
transections [12]. This can subsequently lead to the eventual formation of neuromas 
and scar adhesions. Nerve damage can also be due to indirect injury from postoper-
ative inflammation, hematoma formation, or positioning during surgery (resulting 
in nerve stretching during the procedure) [12]. The nerves most commonly at risk 
for injury during breast cancer surgery are the intercostobrachial nerve (ICBN), the 
thoracic intercostal nerves, medial and lateral pectoral nerves, the thoracodorsal 
nerve, and the long thoracic nerve [13].
Intercostobrachial neuralgia is a well-known cause of persistent pain after breast 
cancer surgery and presents as neuropathic pain in the ipsilateral axilla and arm 
[14]. The ICBN is the lateral cutaneous branch of the second intercostal nerve (T2) 
and is pure sensory in nature [12]. It innervates areas of the axilla, lateral chest wall, 
and aspects of the medial arm (Figure 1), and due to its trajectory and close relation 
to the axillary lymph nodes, is at high risk of injury during axillary lymph node dis-
section and radical mastectomies [16]. Furthermore, a study by Zhu et al. demon-
strated that identification, dissection, and preservation of the ICBN during surgery 
reduced the incidence of persistent pain and improved quality of life for patients 
after breast cancer surgery [17]. While this finding has been observed in additional 
studies [18, 19], it is important to note that while sensitivity was preserved, the 
incidence of reduced pain was not always obtainable [19].
Along with the ICBN, which is a branch of the T2 intercostal nerve, the T3-T6 
intercostal nerves are also at high risk for injury and subsequent intercostal neu-
ralgia. These nerves primarily innervate the skin of the breast, and major branches 
include the rami communicates, the muscular branches, the collateral branch, the 
lateral cutaneous branch, and the anterior cutaneous branch [20]. Involvement 
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of intercostal nerves can present as pain originating at the posterior axillary line 
radiating anteriorly into the chest wall, in the distribution of the affected intercos-
tal nerve. It is not uncommon to have multiple intercostal nerves involved in the 
presentation of persistent pain after breast cancer surgery.
Another nerve, albeit less commonly involved, is the medial cutaneous nerve of 
the arm. This nerve branches from the medial cord of the brachial plexus and can 
form a connection with the ICBN. Damage to this nerve results in sensory loss to the 
lower medial skin of the upper arm [14]. Additionally, neuromas can develop within 
the surgical scar and be a problematic source of persistent pain - scar neuromas are 
an elusive source of pain after any type of surgical procedure.
2.2 Phantom pain
As with other types of amputations, resection of breast tissue is susceptible to 
the development of phantom pain and sensations. Ahmed et al. enrolled eighty 
patients undergoing a modified radical mastectomy and at the one-year mark, 
13.6% experienced phantom pain, while 17% experienced phantom sensation. Its 
lower incidence compared to phantom limb pain may be due to the fact that breasts 
do not involve kinesthetic sensory impulses in the same manner as limbs do [21]. 
Likewise, there may simply be a lack of widespread knowledge and education for 
this condition and thus it may be overlooked in clinical practice. Regardless, while 
less prevalent than neuropathic pain secondary to nerve injury, its importance may 
be greater as treatment options are even more limited [22].
2.3 Perioperative radiation
Radiation therapy can also lead to nerve damage, producing persistent 
peripheral neuropathy. While treatment is targeted, radiation therapy may still 
Figure 1. 
Peripheral nerves innervating the breast. *obtained with permission from Dr. Nelun W ijayasinghe from 
article [15] . II-VI – intercostal nerves II to VI; ICBN – intercostobrachial nerve; LPN  – lateral pectoral 
nerve; LTN  – long thoracic nerve; MPN – medial pectoral nerve; MCN – musculocutaneous nerve;  
TDN – thoracodorsal nerve;
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cause unavoidable injury to nearby nerves such as the brachial plexus, including 
proximal and distal branches. The onset and severity of radiation-induced pain 
can be proportional to the total dose received [23]. A meta-analysis by Wang et 
al. reviewing thirty studies involving 19,813 patients showed an increased likeli-
hood of PMPS among women who underwent radiotherapy [24]. This is likely 
secondary to an increased incidence of tissue fibrosis, which can lead to local 
constriction and compression on nerves and subsequent neural entrapment. 
Furthermore, lymphedema and impaired glenohumeral motion are other sequelae 
that can arise after radiation therapy and lead to the formation of persistent pain 
and morbidity.
2.4 Perioperative chemotherapy
Several commonly used chemotherapy agents such as paclitaxel, vinblastine, and 
vincristine have all been identified as causing residual neuropathic symptoms [25]. 
Peripheral neuropathies are the most common presentation with patients experienc-
ing sensations of numbness and tingling usually in a stocking and glove-like forma-
tion [25]. Unfortunately, those receiving both radiation and chemotherapy tend to 
experience enhanced neuropathic symptoms [26]. The mechanism of chemother-
apy-induced peripheral neuropathy caused by common antineoplastic agents is 
multifactorial. For platinum-based drugs such as oxaliplatin and cisplatin, activation 
of glial cells causes nearby immune cells to release pro-inflammatory cytokines, and 
altered activity in Na+ and K+ ion channels can result in nociceptor sensitization and 
hyperexcitability of peripheral neurons [27]. Vinca alkaloids also cause the release 
of pro-inflammatory mediators and influence microtubule polymerization that 
inhibits axonal transport. This, along with Wallerian degeneration, leads to distal 
axonopathy [27].
3. Risk factors
PMPS is multifactorial in nature and several risk factors have been evaluated for 
their association in the development of persistent pain. Risk factors can be catego-
rized broadly into patient demographics, psychological influence, and surgical and 
anesthetic factors. While an abundance of literature has evaluated risk factors for 
chronic pain, only some consensus exists. Nonetheless, identifying risk factors and 
modifying them early in the perioperative period could potentially help in decreas-
ing the risk of persistent pain in high-risk patients.
3.1 Patient demographics
3 .1 .1  Age
Younger age has been strongly correlated with a higher pain burden index and 
relationship of younger age with persistent pain is well supported [28–31]. This 
finding may be secondary to the fact that younger patients usually present with 
more aggressive, estrogen-receptor negative disease, or higher tumor grade requir-
ing more radical surgeries or adjuvant therapies [32]. Younger patients also tend 
to have greater levels of perioperative anxiety and a lower threshold to pain, when 
compared to older patient groups, thus increasing their overall risk [12]. While 
younger age has been one of the most consistent factors associated with PMPS, 
some reviews have not always found this to be the case [33].
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3 .1 .2  Body Mass Index ( BMI)
Literature also reports that patients with a higher BMI are more likely to experi-
ence persistent pain after breast cancer surgery. A study by Spivey et al. found that 
both a young age and higher BMI correlated with higher pain scores at the six month 
follow up [34], and Juhl et al. showed that a BMI ≥30 kg/m2 was significantly 
associated with persistent pain in both univariate and multivariate models [14]. 
Surprisingly however, a systematic review and meta-analysis of thirty high-grade 
observational studies totaling 19,813 patients showed that BMI was not associated 
with persistent pain [24]. Thus, the correlation may be multifactorial in nature. 
Surgery in obese patients may be associated with more difficult axillary dissections 
due to larger breasts, thus placing them at a higher risk for greater tissue and nerve 
damage. Regardless, as with other surgical disciplines, the risks of perioperative 
complications such as impaired wound healing and increased blood loss remain 
higher in patients with a higher BMI [35, 36].
3.2 Psychological
Several studies have shown a significant correlation between high levels of 
preoperative anxiety [37], catastrophizing symptoms [38], and persistent breast 
pain following breast cancer surgery [34, 39, 40]. Furthermore, there is also a sig-
nificant and independent association between PMPS and somatization, depressive 
symptoms, and sleep disturbance, regardless of the surgical or medical treatment a 
patient received [33]. Furthermore, pain catastrophizing has been found to inten-
sify the experience of both pain and depression [23, 41]. Patients undergoing breast 
surgery may expect to have severe pain after the procedure, thus increasing their 
emotional distress and cause them to excessively focus on only negative aspects such 
as chronic pain. These negative emotions and beliefs may evolve into catastrophic 
thoughts and irrational patterns of thinking and become self-fulfilling in producing 
higher pain levels [42]. In contrast, patients who have a more positive mindset going 
into surgery, and lower levels of emotional distress, are more likely to experiences 
less acute pain [43] and therefore experience a lower incidence of PMPS [40].
3.3 Surgical type
With the advancement of surgical management, the association between surgi-
cal type and chronic pain development seems to vary in the literature. Both breast-
conserving surgery (BCS), with or without lymph node dissection, and radical 
mastectomy have not consistently shown a positive relationship in the development 
of PMPS. A study of 475 patients found that patients who underwent breast-
conserving surgery were at higher risks of developing moderate to severe chronic 
pain at rest (OR 2.0, 95% CI = 1.2–3.3) [30]. Some reports however, indicate that 
more extensive surgery (e.g. radical mastectomies, bilateral procedures, reconstruc-
tion) does lead to greater acute postoperative pain, which in turn is a risk factor in 
developing chronic pain [44]. A prospective, observational study by Spivey et al. 
with 216 patients, and a systematic review and meta-analysis of thirty observational 
studies of 19,813 patients by Wang, et al. both did not observe a significant relation-
ship between surgical type and pain at three and six months, respectively [24, 34].
3.4 Axillary lymph node dissection (ALND)
Lymph node dissection can help with the staging and management of breast 
cancer [45]. Compared to sentinel lymph node biopsy, ALND has been an 
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capsulitis of the glenohumeral joint, myofascial pain syndrome of the pectoral or 
intercostal muscles, and aromatase inhibitor-associated arthralgias (Table 1) [7, 10]. 
Other potential disorders include axillary web syndrome and lymphedema.
When patients present for evaluation of their pain, the first step involves diagnos-
ing the type of pain being experienced. Origin of pain is broadly categorized as either 
nociceptive or neuropathic [54]. In the acute postoperative phase, pain after breast 
surgery is likely to be nociceptive in nature resulting from intraoperative injury and 
subsequent inflammation to tissue, ligaments, or muscles. In order to help diagnose 
the type of pain, and track its severity over time, routine use of questionnaire-based 
assessments are commonly implemented. One that is frequently used is the Douleur 
Neuropathique en 4 (DN4), which consists of two sections – a set of interview ques-
tions and examination findings [55]. The yes/no interview questions ask for the 
presence of burning, painful cold, or electric shocks, and one or more of tingling, pins 
and needles, numbness, and itching. The second section assesses if the patient experi-
ences hypoesthesia to touch or pinprick, and if brushing provokes the pain. With each 
point valued at 1, a total score ≥ 4 signifies a 90% probability of neuropathic pain. 
The questionnaire is quick and reliable, with a sensitivity of 78.0% and specificity of 
81.2% [56].
It is important that a thorough history and physical examination is conducted. 
History will include an evaluation of the patient’s preoperative diagnosis and any 
adjuvant chemotherapy or radiation. Reviewing surgical records will be important 
to establish what type of procedure was conducted (mastectomy versus lumpec-
tomy), whether axillary lymph nodes were resected, if ICBN nerve sparing surgery 
was performed, and if implants or expanders were placed. The anesthesia record 
will also include helpful information on whether perioperative regional anesthetic 
techniques (i.e., Serratus plane or Pectoralis blocks) or intravenous lidocaine infu-
sions were administered — these techniques are known to be effective on reducing 
acute pain but also potentially helpful in preventing persistent pain [10, 57].
Physical examination will include a detailed evaluation of the surgical inci-
sion and surrounding area, documenting any sensory changes. An evaluation for 





Local peripheral nerve injuries - medial and lateral pectoral nerves, intercostal 
nerves, long thoracic, brachial plexopathy
Chemotherapy-induced peripheral neuropathy
Radiation-induced peripheral neuropathy




Others Axillary web syndrome
Lymphedema
*
from previously published article by Dr. James Khan: [1 0 ].
Table 1. 




Approach to the treatment of persistent pain after breast surgery should be 
multimodal and include the use of both non-pharmacological and pharmacological 
therapeutic modalities. The involvement of a multidisciplinary team, including 
an oncologist, pain management specialist, physiotherapist, psychologist, pallia-
tive care specialist, and social worker should be implemented whenever possible. 
Furthermore, a preoperative comprehensive and patient-tailored pain manage-
ment plan should be formulated in advance, which includes education on surgery 
sequelae, the nature and development of their symptoms, and available treatment 
options.
5.1 Non-pharmacological
Non-pharmacological interventions should always be included in the pain man-
agement plan, regardless of whether medications are employed or not. Moreover, 
patients should be aware that non-pharmacological treatments are only one part of 
the overall comprehensive treatment plan. Some patients may actually prefer non-
pharmacological modalities to pharmacological, to avoid risks of drug side effects 
or costs [58].
5 .1 .1  Physical therapy
The initiation of physical therapy (PT) has repeatedly been shown to be benefi-
cial to patients recovering from breast cancer surgery. Range of motion exercises 
and active stretching helps to improve upper extremity strength and function, 
maintain glenohumeral and scapular movement, and allow neuromuscular recruit-
ment with the overall goal of minimizing dysfunction. A systematic review, which 
evaluated the effectiveness of PT after breast cancer surgery, showed that therapy 
involving active exercise and stretching was effective in not only improving range 
of motion but also decreasing postoperative pain [59].
Timing on when to initiate PT has also been studied. Most studies focus on 
implementing PT early in the postoperative period, with clinical practice guidelines 
recommending starting gentle range of motion exercises the day after surgery to 
reduce shoulder dysfunction and pain [60]. Active stretching, followed by strength-
ening, can then be introduced over the next 6–8 weeks [60]. Several studies how-
ever, do report an increase in complications when starting PT too soon after ALND, 
with Schultz et al. suggesting that a delay of one week can help reduce the incidence 
of postoperative seromas [61]. Fortunately, patients taking part in early PT after 
ALND still tend to recover sufficiently by the two-year mark [62].
Besides pain relief, PT has been shown to offer several added benefits to patients 
after breast surgery. A meta-analysis of 56 studies evaluating the effects of exercise 
interventions showed significant benefits in fatigue, depression, body image, 
and health-related quality of life in cancer survivors [63]. As psychological fac-
tors play a known role in the incidence of persistent pain [51], long-term benefits 
can be obtained if practitioners include a PT or exercise course with the hospital 
discharge plan.
5 .1 .2  Psychological therapies
As outlined earlier, psychological factors such as anxiety and catastrophizing 
play a crucial role in the development of persistent pain. Thus, implementing 
various psychological interventions into the treatment plan not only helps with 
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pain control [64], but also allows patients to effectively cope during this challeng-
ing period in their life. Facing a cancer diagnosis, undergoing invasive treatments, 
and managing treatment sequelae can all add to the emotional suffering breast 
cancer patients are faced with. The effectiveness of psychological interventions for 
non-metastatic breast cancer in women was evaluated in twenty-eight randomized 
controlled trials involving 3940 patients. The study showed that psychological 
intervention, in particular cognitive behavioural therapy (CBT), produced favour-
able effects on anxiety, depression, and mood disturbance [65]. Mindfulness-based 
stress reduction (MBSR) has also been examined in breast cancer patients, with a 
recent meta-analysis by Haller et al. evaluating the effectiveness of MBSR in 1709 
patients. MBSR was found to have a significant effect on improving health-related 
quality of life, fatigue, sleep, stress, anxiety, and depression [66].
Perioperative screening questionnaires evaluating psychological stressors, fears, 
and overall mood, such as the Pain Catastrophizing Scale (PCS) or the Amsterdam 
Preoperative Anxiety and Information Scale (APAIS) should be implemented both 
in the pre- and postoperative phase. From this, at-risk patients can be identified and 
the involvement of psychological interventions can be applied. Moreover, with the 
advancement of technology and involvement of virtual care into clinical practice, it 
now allows for easier access and for group therapies to support even larger number 
of participants per session.
5.2 Pharmacological therapy
Treatment with oral analgesics provides a non-invasive approach to treating 
pain, and most patients begin here as they transition from acute to chronic pain. 
Appropriate medication selection relies heavily on obtaining the correct diagnosis, 
patient comorbidities, drug side-effect profiles, and at times, cost. Furthermore, 
we must be cognizant of the chronicity of symptoms and the potential long-term 
consequences of certain therapies, such as with opioids.
A variety of mediation classes have shown to be effective in neuropathic pain, 
and these same classes are effective in patients with chronic neuropathic pain after 
breast cancer surgery. Several guidelines are also available to assist prescribers in 
selecting the most appropriate medication, and second or third line alternatives, if 
necessary [67–69]. Various medication choices by class are briefly outlined in this 
section.
5 .2 .1  Antidepressants
Treatment of neuropathic pain has benefitted from the analgesic properties 
provided by well-studied and familiar anti-depressants. Tricyclic antidepressants 
(TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have become 
common medication choices when treating neuropathic pain [70], albeit usually at 
lower doses than that needed for anti-depressant effects.
Tricyclic antidepressants, such as amitriptyline and nortriptyline, inhibit nor-
epinephrine, serotonin, and adenosine re-uptake at nerve terminals. While not fully 
understood, the increased concentration of these neurotransmitters plays a role in 
the analgesic effects [71]. Furthermore, TCAs also have an antagonistic action at the 
N-methyl-D-aspartate (NMDA) receptor [72], which further helps to reduce pain. 
Doses of TCAs for the treatment of neuropathic pain are much lower than those 
required for depression [73], and may be the reason that the analgesic properties of 
TCAs differ from their anti-depressant properties. The effect of amitriptyline was 
studied in a double-blinded randomized, placebo-controlled crossover trial involving 
15 patients with PMPS [74]. A statistically significant improvement in pain, effect on 
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daily life, and improved sleep was seen, particularly at the 100 mg daily dose. Initial 
starting dose was at 25 mg once daily, and most common adverse effects included tired-
ness, dry mouth, and constipation. While these effects may not be ideal, prescribing 
TCAs to be taken at bedtime may benefit patients who also have difficulty with sleep.
Serotonin-norepinephrine reuptake inhibitors, including duloxetine and 
venlafaxine, also work by inhibiting neurotransmitter reuptake, with venlafaxine 
slightly inhibiting the reuptake of dopamine as well [75]. Both medications have 
been used to treat neuropathic pain and beneficial effects have been reported in the 
literature [76]. Tasmuth et al. evaluated venlafaxine in neuropathic pain follow-
ing breast cancer treatment in patients with pain and sensory disturbances in the 
anterior chest wall, and/or axilla, and/or the median upper arm. While the study 
only examined 15 patients, average pain relief and the maximum pain intensity 
were significantly lower with venlafaxine when compared with placebo [77]. When 
compared to TCAs, venlafaxine has minimal muscarinic and histaminergic activity, 
and the effect of the two medications has been comparable in some studies [78]. 
Furthermore, venlafaxine added to gabapentin has shown enhancement in neuro-
pathic pain relief when the therapies are combined [79].
Along with providing benefit for post-surgical neuropathic pain, both dulox-
etine and venlafaxine also offer pain relief for patient’s suffering from chemother-
apy induced peripheral neuropathy [80, 81], and even decrease motor neuropathy 
symptoms [82]. Benefits of these two SNRIs has been their ability to target multiple 
concerns, such as depression, anxiety, musculoskeletal pain, and neuropathy [83] 
and thus should be strongly considered as an adjuvant when formulating a compre-
hensive pain management plan.
5 .2 .2  Gabapentinoids
Gabapentin and pregabalin are common medications used to treat neuropathic 
pain. While both have structural resemblance to the gamma-aminobutyric acid 
(GABA) neurotransmitter, neither acts as a GABA agonist. Gabapentin’s primary 
mechanism of action is its high-affinity binding to the α2δ subunit of voltage-
activated calcium channels, resulting in a reduction in nerve conduction [84]. 
A retrospective study of 89 patients with persistent breast cancer pain found a 
reduction in pain in 80% of patients with an average gabapentin dose of 1135 mg 
for 14 weeks [85]. Initiating gabapentin at 100-300 mg three times daily, and 
slowly escalating the dose as tolerated, can provide significant pain relief. While 
gabapentin continues to be a first line agent for neuropathic pain, certain draw-
backs must be considered, such as drowsiness, weight gain, and three times a 
day dosing.
Pregabalin works similarly to gabapentin by inhibiting voltage-activated calcium 
channels. It was developed as a successor to gabapentin and has the added benefit 
of being almost completely absorbed in the body, unlike gabapentin. Thus, with 
absorption almost three times that of gabapentin, pregabalin reaches peak blood 
concentrations within one hour after ingestion [86]. Pregabalin has been shown to 
offer significant decrease in VAS pain scores in patients with PMPS [87, 88], along 
with significant improvement in quality of life [88].
5 .2 .3  Opioids
With the general shift away from prescribing narcotics in clinical practice, 
opioid therapy can still play an important role in pain management when used 
appropriately. The need for opioid therapy in the acute postoperative period is com-
mon and can help decrease nociceptive post-surgical pain. Unfortunately, limited 
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data supports the use of opioids for neuropathic pain, especially in the long-term 
[89, 90]. Nonetheless, for cancer patients with continued pain and functional 
impairment, a trial of opioids in carefully selected patients can be beneficial. Local 
and national practice guidelines should be reviewed, risks of adverse effects should 
always be discussed, and signs of tolerance, abuse, addiction, and diversion should 
continually be assessed.
One major benefit of opioid therapy is its synergistic effect when combined 
with other medications. For instance, several studies have demonstrated greater 
pain relief when using gabapentin and an opioid, compared to opioid monotherapy, 
in the treatment of neuropathic pain [91–93]. Not only did combination therapy 
allow for greater reduction in overall pain scores, it also allowed for a decrease in the 
opioid dose. In turn, this helped to decrease the number of adverse effects that arise 
with chronic opioid therapy.
5.3 Interventional therapy
5 .3 .1  Nerve blocks
Several peripheral nerves can be directly targeted for perineural injections with 
local anesthetics, steroids, or even with neurolytic substances such as phenol or 
alcohol. Once the problematic nerves have been identified by a thorough history 
and physical exam, ultrasound guidance can help to visualize the nerves.
The intercostobrachial nerve (ICBN) and specific intercostal nerves can be 
specifically isolated on ultrasound, and medications can be administered under 
real-time visualization. The ICBN can be identified in the same approach as per-
forming an axillary brachial plexus block - with the shoulder abducted 90° and 
externally rotated [94]. The ICBN can be seen posterior to the vessels and just deep 
to the superficial fascia. The medial cutaneous nerve of the arm can also be visual-
ized just anterior to the ICBN [95]. It is important to note that patients experiencing 
pain in the anterior chest wall may not benefit from an ICBN block.
For chest wall pain, especially pain radiating laterally from the posterior to 
the anterior chest, intercostal nerve blocks should be considered. Each intercostal 
nerve branches from the anterior rami of the thoracic spinal nerves and travels on 
the underside of its corresponding rib [96]. Consecutive intercostal nerves can be 
blocked simultaneously under ultrasound guidance with the patient lying prone. 
While the actual nerve may not always be visible on ultrasound, the therapeutic 
solution can be deposited just inferior to the rib, posterior to the pleura, where the 
intercostal nerve resides with its corresponding artery and vein. Due to the location, 
the potential risk of pneumothorax should be explained to the patient, however the 
use of ultrasound decreases this risk [97].
When the pain is not consistent with a specific nerve, or involves a set of mul-
tiple interconnected nerves, various interfascial plane blocks can be an option for 
pain relief. Due to the complexity of innervation to the breast, the serratus anterior 
(SA) plane block helps to cover several small nerve branches altogether [98]. This 
block is approached in a similar manner as individual intercostal nerve blocks, and 
medication is injected in between the latissimus dorsi muscle and the SA muscle. 
Branches of the intercostal nerves can be found both above and below the SA [99] 
and thus some practitioners may choose to deposit additional medication below the 
SA muscle as well. The ICBN perforates the SA muscle in the mid-axillary line and 
can be indirectly captured with this plane block as well [10]. Zocca et al. performed 
the injection on eight patients suffering from PMPS, depositing 0.25% bupivacaine 
and 40 mg of methyl-prednisolone, and all patients had pain relief ranging from 
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